ANIMAL MODELS OF NEUROTRAUMA | JULY 30, 2019
Agoston D.V., McCullough J., Aniceto R., Kamnaksh A., Wright D.K., Shultz S.R.
Animal Models of Neurotrauma New York, NY: Springer New York; 2019: 263-294.
doi: https://doi.org/10.1007/978-1-4939-9711-4_16
ABSTRACT
There is an unquestionably large translational gap between experimental and clinical traumatic brain injury (TBI) studies. The “lost in translation” factor is reflected in the zero success rates of clinical trials for TBI forcing pharmaceuticals to eliminate or drastically reduce their R&D budgets for developing pharmacotherapies for TBI. Of the many factors contributing to the current translational block is the difference in outcome measures used in experimental versus clinical TBI studies, essentially forcing scientists to compare “apples to oranges.”
Here, we describe selected clinically relevant outcome measures scientists in experimental TBI can and should employ. We specifically focus on neurobehavioral, imaging and biochemical outcome measures which all have clinical equivalents. Our goal is to provide scientists with detailed descriptions of methodologies hoping that increasing numbers of experimental TBI studies will use them resulting in narrowing the translational gap between experimental and clinical TBI studies.
Related Posts
Next-Generation PhenoCode Molecular Barcoding Chemistry: Enhanced Reliability and Reproducibility for High-Plex Spatial Profiling
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…